Giovanna Elisiana Carpagnano

Giovanna Elisiana Carpagnano

Auto-generated profile, based on publicly available information

Giovanna Elisiana Carpagnano

Institute of Respiratory Disease, Department of Translational Biomedicine and Neuroscience, University “Aldo Moro”, 70121 Bari, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2017 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
Ildikó HorváthIldikó Horváth
Ildikó Horváth
PBPeter Barnes
Peter Barnes
SLStelios Loukides
Stelios Loukides
PSPeter J. Sterk
Peter J. Sterk
MHMarieann Högman
Marieann Högman
TVTeunis J. Vink
Teunis J. Vink
Breath tests cover the fraction of nitric oxide in expired gas (FENO), volatile organic compounds (VOCs), variables in exhaled breath condensate (EBC) and other measurements. For EBC and forFENO, official recommendations for standardised procedures are more than 10 years old and there is none for exhaled VOCs and particles. The aim of this document is to provide technical standards and recommendations for sample collection and analytic approaches and to highlight future research priorities in the field. For EBC andFENO, new developments and advances in technology have been evaluated in the current document. This report is not intended to provide clinical guidance on disease diagnosis and management.Clinicians and researchers with expertise in exhaled biomarkers were invited to participate. Published studies regarding methodology of breath tests were selected, discussed and evaluated in a consensus-based manner by the Task Force members.Recommendations for standardisation of sampling, analysing and reporting of data and suggestions for research to cover gaps in the evidence have been created and summarised.Application of breath biomarker measurement in a standardised manner will provide comparable results, thereby facilitating the potential use of these biomarkers in clinical practice.

1 October 2003 in Chest
Verified
Journal Article
Closed access
GCGiovanna E. Carpagnano
Giovanna E. Carpagnano
SKSergei A. Kharitonov
Sergei A. Kharitonov
OROnofrio Resta
Onofrio Resta
MBMaria Pia Foschino Barbaro
Maria Pia Foschino Barbaro
EGEnzo Gramiccioni
Enzo Gramiccioni
PBPeter Barnes
Peter Barnes

9 August 2020 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
GCG. E. Carpagnano
G. E. Carpagnano
VLValentina Di Lecce
Valentina Di Lecce
Vitaliano Nicola QuarantaVitaliano Nicola Quaranta
Vitaliano Nicola Quaranta
AZA. Zito
A. Zito
EBEnrico Buonamico
Enrico Buonamico
ORO. Resta
O. Resta
Purpose: Hypovitaminosis D is a highly spread condition correlated with increased risk of respiratory tract infections. Nowadays, the world is in the grip of the Coronavirus disease 19 (COVID 19) pandemic. In these patients, cytokine storm is associated with disease severity. In consideration of the role of vitamin D in the immune system, aim of this study was to analyse vitamin D levels in patients with acute respiratory failure due to COVID-19 and to assess any correlations with disease severity and prognosis. Methods: In this retrospective, observational study, we analysed demographic, clinical and laboratory data of 42 patients with acute respiratory failure due to COVID-19, treated in Respiratory Intermediate Care Unit (RICU) of the Policlinic of Bari from March, 11 to April 30, 2020. Results: Eighty one percent of patients had hypovitaminosis D. Based on vitamin D levels, the population was stratified into four groups: no hypovitaminosis D, insufficiency, moderate deficiency, and severe deficiency. No differences regarding demographic and clinical characteristics were found. A survival analysis highlighted that, after 10 days of hospitalization, severe vitamin D deficiency patients had a 50% mortality probability, while those with vitamin D ≥ 10 ng/mL had a 5% mortality risk (p = 0.019). Conclusions: High prevalence of hypovitaminosis D was found in COVID-19 patients with acute respiratory failure, treated in a RICU. Patients with severe vitamin D deficiency had a significantly higher mortality risk. Severe vitamin D deficiency may be a marker of poor prognosis in these patients, suggesting that adjunctive treatment might improve disease outcomes.

1 October 2002 in Chest
Verified
Journal Article
Closed access
GCGiovanna E. Carpagnano
Giovanna E. Carpagnano
SKSergei A. Kharitonov
Sergei A. Kharitonov
OROnofrio Resta
Onofrio Resta
MBMaria Pia Foschino Barbaro
Maria Pia Foschino Barbaro
EGEnzo Gramiccioni
Enzo Gramiccioni
PBPeter Barnes
Peter Barnes

1 December 2004 in Thorax
Verified
Journal Article
Open access
PDF file
GCG E Carpagnano
G E Carpagnano
SKS A Kharitonov
S A Kharitonov
MBMaria Pia Foschino Barbaro
Maria Pia Foschino Barbaro
ORO Resta
O Resta
EGE Gramiccioni
E Gramiccioni
PBPeter Barnes
Peter Barnes
Background: Hyperoxia increases oxidative stress through the generation of reactive oxygen species and may therefore enhance inflammation in the lungs. The aim of this study was to investigate whether short term supplementary oxygen (28%) increases oxidative stress and inflammation in the airways by measuring 8-isoprostane and interleukin 6 (IL-6) concentrations in exhaled breath condensate. Methods: Twenty three healthy subjects (12 men, mean (SD) age 48 (7) years) and 23 patients with chronic obstructive pulmonary disease (COPD; 15 men, mean (SD) age 56 (5) years) were studied. 8-isoprostane and IL-6 concentrations were measured by immunoassay. Results: Increased concentrations of 8-isoprostane and IL-6 were found in all subjects after breathing 28% oxygen for 1 hour. In healthy subjects the concentrations of 8-isoprostane and IL-6 were 10.9 (2.9) pg/ml and 4.9 (0.8) pg/ml, respectively, compared with baseline concentrations of 6.1 (1.3) pg/ml and 2.9 (0.6) pg/ml, and in patients with COPD the concentrations were 27.9 (3.1) pg/ml and 8.3 (1.2) pg/ml), respectively, compared with baseline concentrations of 18.9 (3.6) pg/ml and 6.3 (0.6) pg/ml. By contrast, breathing air through the same face mask for 1 hour had no significant effects on 8-isoprostane or IL-6 concentrations in normal subjects or those with COPD. Conclusions: These findings suggest that short term supplementary oxygen may enhance oxidative stress and inflammation in the airways. Whether this happens with long term oxygen therapy needs to be determined.

15 April 2003 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GCGiovanna E. Carpagnano
Giovanna E. Carpagnano
PBPeter Barnes
Peter Barnes
DGDuncan M. Geddes
Duncan M. Geddes
MHMargaret E. Hodson
Margaret E. Hodson
SKSergei A. Kharitonov
Sergei A. Kharitonov
Chronic neutrophilic airway inflammation is an important feature of cystic fibrosis (CF). Noninvasive inflammatory markers may be useful in monitoring CF. Leukotriene B4 (LTB4) and interleukin (IL)-6 are inflammatory mediators that are increased in chronic neutrophilic inflammation. The aim of this study was to assess whether LTB4 and IL-6 were increased in exhaled breath condensate of CF patients and whether they could be used to monitor inflammation. Twenty patients with CF (13 males, age of 28 ± 9 years) were recruited together with 15 age-matched healthy subjects (8 males, age 35 ± 7 years). LTB4 and IL-6 levels were markedly elevated in patients with acute exacerbations (28.8 ± 4.3 and 8.7 ± 0.4 pg/ml) compared with control subjects (6.8 ± 0.7 and 2.6 ± 0.1 pg/ml, p < 0.0001). We also observed a decrease of exhaled LTB4 and IL-6 concentrations after antibiotic treatment in six patients who were followed until clinically stable (31.1 ± 4.4 and 9.5 ± 0.4 pg/ml vs. 18.8 ± 0.8 and 6.4 ± 0.2 pg/ml, respectively) and an increase in 15 CF patients infected with Pseudomonas aeruginosa (34.3 ± 5.0 and 9.3 ± 0.3 pg/m) compared with those infected with other bacteria (18.3 ± 0.7 and 6.9 ± 0.5 pg/ml). These findings suggest that LTB4 and IL-6 levels are increased in exhaled breath condensate of patients with CF during exacerbation and could be used to monitor airway inflammation in these patients.